Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Safety Evaluation of Nafamostat Mesilate During Continuous Renal Replacement Therapy in Critically Ill Patients

NCT05382078 is registered in ClinicalTrials.gov with First Affiliated Hospital Xi'an Jiaotong University as lead sponsor.

NCT NCT05382078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05382078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Safety Evaluation of Nafamostat Mesilate During Continuous Renal Replacement Therapy in Critically Ill Patients
Lead sponsor
First Affiliated Hospital Xi'an Jiaotong University
Phase
Observational
Overall status
Unknown status
Start date
May 31, 2022
Completion date
May 3, 2024
Enrollment
188 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aki, hemorrhage, mods, sepsis syndrome, thrombus, trauma